Recently, after preliminary research, audit evaluation, submission of materials and other necessary links, our company successfully passed the audit and became the first batch of high-tech enterprises to be recognized in Shanghai in 2020!

On November 28, 2019, Shanghai Luoqi Bio-pharmaceutical Technology Co., Ltd. performed well in enterprise operation, research and development management, intellectual property rights, talent introduction and other aspects after being reviewed and recognized by the Shanghai Municipal Science and Technology Commission, and was successfully approved for the warehousing and cultivation of high-tech enterprises in Shanghai in 2019.

On October 16, 2019, Shanghai Luoqi Biology and Professor Yang Zhi of the Department of Nuclear Medicine of Peking University Cancer Hospital cooperated to publish a research paper entitled "Construction of anti-hPD-L1 HCAb Nb6 and in situ 124I labeling for noninvasive detection of PD-L1 expression in human bone sarcoma" in BIOCONJUGATE CHEMISTRY, and invited to publish it as a cover article.

On November 14, 2019, after the review of the Shanghai Pudong New Area Science and Technology and Economic Commission, Luoqi Biology performed well in terms of enterprise operation, R&D investment, intellectual property, talent introduction and venture capital acquisition in the previous year, and won the special fund for key technology entrepreneurship enterprises in Pudong New Area science and technology development.

In October 2019, the latest research result of Shanghai Luoqi Biotechnology Co., Ltd., "Blocking the PD-1-PD-L1 axis by a novel PD-1specific Nanobody expressed in year as a potential thermal forever", was published in the journal of Biological and Biophysical Research Communications under ELSEVIER.

From September 28 to October 2, 2019, the 29th ERS (European Respiratory Society Annual Conference) was held in Madrid, Spain. More than 20000 colleagues from all over the world participated in the event. This ERS meeting covered the key topics of respiratory medicine in 14 scientific fields, including tuberculosis, lung cancer, chronic and acute respiratory failure, sleep disordered breathing, interstitial lung disease, pneumonia, cystic fibrosis, COPD and asthma.

On July 26, the 2019 Mid-Year Work Summary Meeting of Luoqi Biology was held in the Phase III Exhibition Center of Shanghai International Medical Park. All staff of the company attended the meeting, which was presided over by Zhu Min, assistant general manager.

On April 11, 2019, Shanghai Luoqi Bio-pharmaceutical Technology Co., Ltd. won the bid for the 2019 "Science and Technology Innovation Action Plan" in the field of biomedicine science and technology support project in Shanghai.

On March 1, 2019, Shanghai Luoqi Bio-pharmaceutical Technology Co., Ltd. and Zhejiang Terex Pharmaceutical Co., Ltd. signed a global strategic cooperation agreement, announcing that the two sides will carry out cooperation in various aspects in the field of tumor immunotherapy and nano-antibody drugs, with strong cooperation, complementary advantages and win-win cooperation. Dr. Wan Yakun, chairman of Rocky Biology, and Dr. Wu Youling, chief executive officer and chairman of Trisys Pharmaceutical attended the ceremony and signed. Xiong Quanlong, deputy director of the Standing Committee of Huzhou Municipal People's Congress and secretary of the Party Committee of the Development Zone, attended the ceremony and delivered an important speech.

On October 30, Luoqi Biology was invited to participate in the "Opening Ceremony of the 8th China Innovation and Entrepreneurship Competition (Shanghai) and 2019 Entrepreneurship in Shanghai International Innovation and Entrepreneurship Competition". At the ceremony, relevant leaders presented awards to the winners of the 2018 "Entrepreneurship in Shanghai" International Innovation and Entrepreneurship Competition.